苯环利定盐酸盐 | 956-90-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 苯环利定盐酸盐
• 中文别名: PCP盐酸盐；1-(1-苯基环己基)哌啶盐酸盐；盐酸苯环利定
• 英文名称: phencyclidine hydrochloride
• 英文别名: 1-[1-(phenylcyclohexyl)]piperidine hydrochloride；1-(1-phenylcyclohexyl)piperidine hydrochloride；1-[1-phenylcyclohexyl]piperidine hydrochloride；phenylcyclidine hydrochloride；phenacyclidine hydrochloride；phencyclidine*HCl；1-(1-phenylcyclohexyl)piperidine;hydrochloride
• CAS: 956-90-1
• 化学式: C₁₇H₂₅N*ClH
• 分子量: 279.853
• InChiKey: BUAJNGPDPGKBGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.08
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  4.4
• 氢给体数：
  1
• 氢受体数：
  1

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：已报告一例使用苯环利定（PCP）的案例，在使用未知数量药物6周后，母乳中检测到少量苯环利定。对哺乳婴儿的影响未知。 母乳喂养医学学会建议，一般来说，滥用苯环利定的妇女在分娩时尿检呈阴性，已戒断至少90天，正在参加物质滥用治疗计划并计划在产后期继续参与，获得物质滥用顾问的批准，积极参与并遵守产前护理，且没有其他母乳喂养的禁忌症时，才可以进行母乳喂养。 ◉ 哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:A single case of phencyclidine use has been reported in which a small amount of phencyclidine was detected in breastmilk over 6 weeks after use of an unknown quantity of the drug. Effects on the breastfed infant are unknown. The Academy of Breastfeeding Medicine suggests that women who have abused phencyclidine generally should not breastfeed unless they have a negative maternal urine toxicology at delivery, have been abstinent for at least 90 days, are in a substance abuse treatment program and plan to continue in it during the postpartum period, have the approval of their substance abuse counselor, have been engaged and compliant in their prenatal care, and have no other contraindications to breastfeeding. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：已报告一例使用苯环利定（PCP）的案例，在使用未知数量药物6周后，母乳中检测到少量苯环利定。对哺乳婴儿的影响未知。 母乳喂养医学学会建议，一般来说，滥用苯环利定的妇女在分娩时尿检呈阴性，已戒断至少90天，正在参加物质滥用治疗计划并计划在产后期继续参与，获得物质滥用顾问的批准，积极参与并遵守产前护理，且没有其他母乳喂养的禁忌症时，才可以进行母乳喂养。 ◉ 哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:A single case of phencyclidine use has been reported in which a small amount of phencyclidine was detected in breastmilk over 6 weeks after use of an unknown quantity of the drug. Effects on the breastfed infant are unknown. The Academy of Breastfeeding Medicine suggests that women who have abused phencyclidine generally should not breastfeed unless they have a negative maternal urine toxicology at delivery, have been abstinent for at least 90 days, are in a substance abuse treatment program and plan to continue in it during the postpartum period, have the approval of their substance abuse counselor, have been engaged and compliant in their prenatal care, and have no other contraindications to breastfeeding. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为反应物：
  描述：

  苯环利定盐酸盐 以 水 为溶剂， 反应 312.0h， 生成 1-(1-苯基环己基)-4-羟基哌啶 、 r-4-phenyl-4-(1-piperidinyl)-c-cyclohexanol
  参考文献：
  名称：

  苯环利定被微生物代谢。

  摘要：

  筛选了许多微生物的代谢苯环利定的能力。通过高压液相色谱分析，两种微生物，白僵菌和马鞭草（Cunninghamella echinulata）产生羟基化的代谢产物，它们被鉴定为1-（1-苯基环己基）-4-羟基哌啶和4-苯基-4-哌啶基环己醇。

  DOI：

  10.1002/jps.2600700210
• 作为产物：
  描述：

  哌啶 、 环己酮 在 碘 、 sodium hydrogensulfite 、 magnesium 作用下， 以 乙醚 为溶剂， 生成 苯环利定盐酸盐
  参考文献：
  名称：

  苯环利定的新吗啉类似物：大鼠的化学合成和疼痛知觉。

  摘要：

  苯环利定（PCP，I）及其大多数衍生物已显示出某些药理作用。因此，在这项研究中，合成了新的甲氧基（III）和羟基甲基（IV）吗啉PCP衍生物。通过尾部浸泡和福尔马林试验对这些药物（III，IV）的急性和慢性疼痛活性进行了研究，并将结果与​​PCP，PCM（PCP-吗啉，II）和甲基-PCM（V）的结果进行了比较。 。研究结果表明，在注射后20、40、45和55分钟内，与I和II相比，III（6 mg / kg，ip）在尾部浸泡试验中产生了更多的镇痛作用。静脉注射（相同剂量）后10、20、40、45和50分钟观察到这些效果。这种镇痛作用显着出现在20，40，45和50分钟后的化合物IV与药物（比较的应用IV）。在福尔马林测试分析中，这些新的合成药物（III和IV）可以减轻急性化学性疼痛（第一阶段）不受任何药物（IV）的影响，而慢性福尔马林的疼痛可以减少（尤其是在第二阶段后期）到我和II以6毫

  DOI：

  10.1016/j.pbb.2010.12.019

文献信息

• [EN] 3-(1,2,3,6-TETRAHYDROPYRIDIN-2-YL)PYRIDINE GLUTARATE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF<br/>[FR] 3- (1,2,3,6-TÉTRAHYDROPYRIDIN-2-YL) PYRIDINE GLUTARATE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI
  申请人：PHILIP MORRIS PRODUCTS SA

  公开号：WO2020127225A1

  公开（公告）日：2020-06-25

  The present invention relates to 3 -( 1,2,3,6-tetrahydropyridin-2-yI)pyridine glutarate or a pharmaceutically acceptable solvate thereof, to a crystal thereof and to a polymorph of this crystal It further relates to the medicinal use of each of these, in particular in the treatment or prophylaxis of substance addiction or inflammation

  这项发明涉及3-(1,2,3,6-四氢吡啶-2-基)吡啶戊二酸盐或其药用可溶剂结晶体，以及该结晶体的多晶形态。此外，还涉及这些物质的药用，特别是在治疗或预防物质成瘾或炎症方面的用途。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• AMINOCYCLOBUTANE DERIVATIVES, METHOD FOR PREPARING SAME AND THE USE THEREOF AS DRUGS
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20150315132A1

  公开（公告）日：2015-11-05

  The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. These compounds correspond to the general formula (1): wherein: X 1 represents a hydrogen atom or fluorine atom; X 2 is a hydrogen atom or fluorine atom or chlorine atom; R1 represents a hydrogen atom or fluorine atom or chlorine atom or methyl group or methoxy group or cyano group; R2 represents independently or together a methyl group or ethyl group.

  目前的发明涉及氨基环丁烷的衍生物，特别是作为NMDA受体拮抗剂，在人类治疗中的应用以及它们的制备方法。这些化合物对应于一般式（1）：其中：X1代表氢原子或氟原子；X2是氢原子或氟原子或氯原子；R1代表氢原子或氟原子或氯原子或甲基基团或甲氧基团或氰基；R2独立或一起代表甲基基团或乙基基团。
• [EN] COMPOUNDS HAVING SEROTONIN 5-HT17 RECEPTOR ANTAGONIST ACTIVITY AND MUSCARINIC M4 RECEPTOR AGONIST ACTIVITY AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE ANTAGONISTE DU RECEPTEUR DE LA SEROTONINE 5-HT17 ET UNE ACTIVITE AGONISTE DU RECEPTEUR MUSCARINIQUE M4 ET UTILISATION DE CES COMPOSES POUR LE TRAITEMENT DES TROUBLES PSYCHOTIQUES
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2004087124A1

  公开（公告）日：2004-10-14

  The present invention relates to novel treatments for schizophrenia, based on the concept of identifying agents capable of selectively binding to the serotonin 5-HT7 and muscarinic M4 receptors and the use of such compounds in treating schizophrenia. The present invention also relates to novel amidine compounds for treating schizophrenia, a method of manufacturing such compounds, pharmaceutical formulations comprising said compounds, as well as medical uses and methods of treatment using said compounds.

  本发明涉及基于识别能够选择性结合到5-羟色胺5-HT7和肌碱M4受体的药剂，并将这类化合物用于治疗精神分裂症的新型治疗方法。本发明还涉及用于治疗精神分裂症的新型胺基化合物，一种制造这类化合物的方法，包含该化合物的药物配方，以及使用该化合物进行治疗的医疗用途和治疗方法。